Mar 6 |
GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System
|
Mar 1 |
GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript
|
Feb 29 |
GeoVax GAAP EPS of -$14.29 beats by $0.26
|
Feb 29 |
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
|
Feb 29 |
Earnings Scheduled For February 29, 2024
|
Feb 28 |
Earnings Outlook For Geovax Labs
|
Feb 23 |
InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
|
Feb 19 |
GeoVax to Present at the 2024 BIO CEO & Investor Conference
|
Feb 6 |
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
|
Jan 29 |
GeoVax Labs to effect 1-for-15 reverse stock split to regain compliance with Nasdaq rule
|